Archive: February 2024
Feature
A Review of New Concepts in Iron Overload
Abstract: Iron overload disorders are conditions that can lead to increased body iron stores and end-organ damage in affected organs. Increased iron deposition most commonly occurs […]
Feature
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy
Abstract: The COVID-19 pandemic introduced significant uncertainty regarding the care of patients with inflammatory bowel disease (IBD). Substantial research efforts have made progress in answering many […]
Feature
Esophagogastric Junction Outflow Obstruction: A Diagnosis in Evolution
Abstract: Esophagogastric junction outflow obstruction (EGJOO) is a rapidly evolving diagnosis that can represent early or variant achalasia. Since the publication of the Chicago Classification version […]
Letter From the Editor
Letter From the Editor: Exploring Vaccination in Patients With Inflammatory Bowel Disease
Vaccination has become a polarizing issue in the United States, as Dr Francis A. Farraye notes in this month’s issue of Gastroenterology & Hepatology. Two of […]
Advances in Hepatology
Reflecting on a Decade of Sofosbuvir Use for Hepatitis C Virus Treatment
G&H Sofosbuvir was approved with ribavirin or pegylated interferon plus ribavirin just over 10 years ago for the treatment of hepatitis C virus infection. Thinking back […]
Advances in IBD
Reviewing Recommendations for Vaccines and Health Care Maintenance in Patients With Inflammatory Bowel Disease
G&H What are the current recommendations for influenza and respiratory syncytial virus vaccines in patients with inflammatory bowel disease? FF All patients with inflammatory bowel disease […]
HCC in Focus
Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma
G&H What is the rationale for using durvalumab and tremelimumab in combination for the treatment of hepatocellular carcinoma? RK Durvalumab (Imfinzi, AstraZeneca) and tremelimumab (Imjudo, AstraZeneca) […]